Roche partners with China's Defand Therapeutics on molecular glues

· Health · Switzerland · China

Roche is teaming up with Hangzhou, China-based startup Defand Therapeutics to discover new molecular glue and protein degrader medicines, marking the Swiss pharma's fourth China deal since August. The agreement is worth just short of $1 billion if all milestones are achieved, according to a source familiar with the terms. Defand is a relatively unknown biotech, and the structure goes beyond a simple licensing arrangement. The deal deepens a trend of Western pharmaceutical companies looking to Chinese biotech for early-stage science, particularly in targeted protein degradation, as they seek to replenish pipelines.

Why it matters：The steady cadence of Roche's China licensing deals signals that Chinese biotech labs are becoming a default source of early-stage molecules, reshaping how large pharma sources innovation and where competitive advantage in drug discovery sits.

Key points

  • The deal value approaches $1 billion if all milestones are met.
  • It is Roche's fourth China partnership since August.
  • The focus is molecular glue medicines and protein degraders.

Sources (original reporting)

More stories from this day